Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives

Extracellular vesicles (EVs) have emerged as a potential therapy for several diseases. These plasma membrane-derived fragments are released constitutively by virtually all cell types—including mesenchymal stromal cells (MSCs)—under stimulation or following cell-to-cell interaction, which leads to ac...

Full description

Bibliographic Details
Main Authors: Soraia C. Abreu, Miquéias Lopes-Pacheco, Daniel J. Weiss, Patricia R. M. Rocco
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.600711/full
id doaj-9435e400a51f4df4b4c93fc98cf378bd
record_format Article
spelling doaj-9435e400a51f4df4b4c93fc98cf378bd2021-02-15T05:29:53ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-02-01910.3389/fcell.2021.600711600711Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and PerspectivesSoraia C. Abreu0Soraia C. Abreu1Miquéias Lopes-Pacheco2Daniel J. Weiss3Patricia R. M. Rocco4Patricia R. M. Rocco5Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilNational Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, BrazilBiosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, Lisbon, PortugalDepartment of Medicine, College of Medicine, University of Vermont Larner, Burlington, VT, United StatesLaboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilNational Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, BrazilExtracellular vesicles (EVs) have emerged as a potential therapy for several diseases. These plasma membrane-derived fragments are released constitutively by virtually all cell types—including mesenchymal stromal cells (MSCs)—under stimulation or following cell-to-cell interaction, which leads to activation or inhibition of distinct signaling pathways. Based on their size, intracellular origin, and secretion pathway, EVs have been grouped into three main populations: exosomes, microvesicles (or microparticles), and apoptotic bodies. Several molecules can be found inside MSC-derived EVs, including proteins, lipids, mRNA, microRNAs, DNAs, as well as organelles that can be transferred to damaged recipient cells, thus contributing to the reparative process and promoting relevant anti-inflammatory/resolutive actions. Indeed, the paracrine/endocrine actions induced by MSC-derived EVs have demonstrated therapeutic potential to mitigate or even reverse tissue damage, thus raising interest in the regenerative medicine field, particularly for lung diseases. In this review, we summarize the main features of EVs and the current understanding of the mechanisms of action of MSC-derived EVs in several lung diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary infections [including coronavirus disease 2019 (COVID-19)], asthma, acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF), among others. Finally, we list a number of limitations associated with this therapeutic strategy that must be overcome in order to translate effective EV-based therapies into clinical practice.https://www.frontiersin.org/articles/10.3389/fcell.2021.600711/fullbiomarkerscell therapyextracellular vesiclesinflammationremodelingrespiratory disease
collection DOAJ
language English
format Article
sources DOAJ
author Soraia C. Abreu
Soraia C. Abreu
Miquéias Lopes-Pacheco
Daniel J. Weiss
Patricia R. M. Rocco
Patricia R. M. Rocco
spellingShingle Soraia C. Abreu
Soraia C. Abreu
Miquéias Lopes-Pacheco
Daniel J. Weiss
Patricia R. M. Rocco
Patricia R. M. Rocco
Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
Frontiers in Cell and Developmental Biology
biomarkers
cell therapy
extracellular vesicles
inflammation
remodeling
respiratory disease
author_facet Soraia C. Abreu
Soraia C. Abreu
Miquéias Lopes-Pacheco
Daniel J. Weiss
Patricia R. M. Rocco
Patricia R. M. Rocco
author_sort Soraia C. Abreu
title Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
title_short Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
title_full Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
title_fullStr Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
title_full_unstemmed Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
title_sort mesenchymal stromal cell-derived extracellular vesicles in lung diseases: current status and perspectives
publisher Frontiers Media S.A.
series Frontiers in Cell and Developmental Biology
issn 2296-634X
publishDate 2021-02-01
description Extracellular vesicles (EVs) have emerged as a potential therapy for several diseases. These plasma membrane-derived fragments are released constitutively by virtually all cell types—including mesenchymal stromal cells (MSCs)—under stimulation or following cell-to-cell interaction, which leads to activation or inhibition of distinct signaling pathways. Based on their size, intracellular origin, and secretion pathway, EVs have been grouped into three main populations: exosomes, microvesicles (or microparticles), and apoptotic bodies. Several molecules can be found inside MSC-derived EVs, including proteins, lipids, mRNA, microRNAs, DNAs, as well as organelles that can be transferred to damaged recipient cells, thus contributing to the reparative process and promoting relevant anti-inflammatory/resolutive actions. Indeed, the paracrine/endocrine actions induced by MSC-derived EVs have demonstrated therapeutic potential to mitigate or even reverse tissue damage, thus raising interest in the regenerative medicine field, particularly for lung diseases. In this review, we summarize the main features of EVs and the current understanding of the mechanisms of action of MSC-derived EVs in several lung diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary infections [including coronavirus disease 2019 (COVID-19)], asthma, acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF), among others. Finally, we list a number of limitations associated with this therapeutic strategy that must be overcome in order to translate effective EV-based therapies into clinical practice.
topic biomarkers
cell therapy
extracellular vesicles
inflammation
remodeling
respiratory disease
url https://www.frontiersin.org/articles/10.3389/fcell.2021.600711/full
work_keys_str_mv AT soraiacabreu mesenchymalstromalcellderivedextracellularvesiclesinlungdiseasescurrentstatusandperspectives
AT soraiacabreu mesenchymalstromalcellderivedextracellularvesiclesinlungdiseasescurrentstatusandperspectives
AT miqueiaslopespacheco mesenchymalstromalcellderivedextracellularvesiclesinlungdiseasescurrentstatusandperspectives
AT danieljweiss mesenchymalstromalcellderivedextracellularvesiclesinlungdiseasescurrentstatusandperspectives
AT patriciarmrocco mesenchymalstromalcellderivedextracellularvesiclesinlungdiseasescurrentstatusandperspectives
AT patriciarmrocco mesenchymalstromalcellderivedextracellularvesiclesinlungdiseasescurrentstatusandperspectives
_version_ 1724269209370755072